Search The Medical Knowledge Base

Drug Details

TEKAMLO

• Presentation
  Tablets (aliskiren/amlodipine): 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg, 300 mg/10 mg. (3)
• Description
  Tablet form.
• Indications
  

  Tekamlo is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of
  hypertension:

  • As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
  • In patients not adequately controlled with monotherapy.
  • As a substitute for its titrated components.

• Adult Dosage
  

  • Add-on therapy or initial therapy: Initiate with 150 mg/5 mg. Titrate as needed up to a maximum of 300 mg/10 mg.
  • The blood pressure lowering effect is largely attained within 1-2 weeks.
  • Replacement therapy: may substitute for titrated components.
  • Administer one tablet daily with a routine pattern with regard to meals.
  • May administer with other antihypertensive agents.
  • Additive effects with ACE inhibitors at maximal doses have not been studied.

• Special Precautions
  

  • Avoid fetal and neonatal exposure.
  • Head and neck angioedema: Discontinue Tekamlo and monitor until signs and symptoms resolve.
  • Hypotension in volume- and/or salt-depleted patients: Correct imbalances before initiating therapy with Tekamlo.
  • Increased angina or myocardial infarction with calcium channel blockers may occur upon dosage initiation or increase.
  • Patients with renal impairment: Decrease in renal function may be anticipated with susceptible individuals.
  • Patients with hepatic impairment: Titrate slowly.
  • Patients with heart failure: Titrate slowly.
  • Hyperkalemia: Monitor serum potassium when co-administering with ACEI, potassium-sparing diuretics, potassium supplements, or other
  potassium-containing salt substitutes.

• Adverse Drug Reactions
  

  The most common adverse event (incidence ≥2 % and more common than with placebo) is peripheral edema.